|
Market Closed -
Nasdaq
08:00:00 19/11/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 945.53 USD | -1.28% |
|
-1.45% | +22.50% |
| 10:10am | US FDA approves Regeneron's drug for generalized myasthenia gravis | RE |
| 19/11 | Regeneron Pharmaceuticals Insider Sold Shares Worth $1,917,945, According to a Recent SEC Filing | MT |
| Market Cap | 96.11B 87.58B 80.97B 73.07B 138B 8,982B 143B 976B 386B 4,847B 361B 353B 15,312B | P/E 2026 * |
16.2x | P/E 2027 * | 15.4x |
|---|---|---|---|---|---|
| Enterprise Value | 88.94B 81.05B 74.93B 67.62B 127B 8,312B 133B 903B 357B 4,486B 334B 327B 14,170B | EV / Sales 2026 * |
4.73x | EV / Sales 2027 * | 4.14x |
| Free-Float |
72.51% | Yield 2026 * |
0.39% | Yield 2027 * | 0.42% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| REGN | Delayed | |
| REGN | Real-time | ||
| REGN * | End-of-day quote | ||
| RGO | Real-time | ||
| RGO | Real-time | ||
| 0R2M | Delayed | ||
| RGO | Delayed | ||
| RGO | End-of-day quote | ||
| RGO | Delayed | ||
| 1REGN | End-of-day quote | ||
| REGN | End-of-day quote | ||
| REGNUS | End-of-day quote |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -1.28% | ||
| 1 week | -1.45% | ||
| Current month | +1.90% | ||
| 1 month | +20.91% | ||
| 3 months | +16.70% | ||
| 6 months | +50.16% | ||
| Current year | +22.50% |
| 1 week | 942 | 981.55 | |
| 1 month | 780.83 | 991.73 | |
| Current year | 591.52 | 991.73 | |
| 1 year | 591.52 | 991.73 | |
| 3 years | 476.49 | 1,211.2 | |
| 5 years | 476.49 | 1,211.2 | |
| 10 years | 271.37 | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
George Sing
BRD | Director/Board Member | 76 | 08/01/1988 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/11/26 | Exercice | SVP Controller | 11,828 | 0.0117% | ||
| 3/11/26 | Exercice | Director | 22,317 | 0.0221% | ||
| 3/11/26 | Don | Chief Technology Officer | -1,054 | 0.0010% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.28% | -1.45% | +30.36% | +17.95% | 96.11B | ||
| -2.32% | -3.79% | +34.24% | +131.38% | 1,261B | ||
| -2.15% | -2.75% | +36.35% | +81.91% | 671B | ||
| -2.33% | -3.04% | +22.29% | +106.79% | 518B | ||
| -0.69% | +0.40% | +40.46% | +69.78% | 387B | ||
| -3.90% | -6.39% | +42.88% | +34.18% | 353B | ||
| -1.35% | -2.23% | +24.30% | +56.34% | 300B | ||
| -1.13% | -1.71% | +0.40% | +33.00% | 283B | ||
| -3.07% | -5.17% | +29.04% | +67.28% | 248B | ||
| -0.75% | -0.44% | +32.87% | +122.34% | 211B | ||
| Average | -1.45% | +0.02% | +29.32% | +72.10% | 433B | |
| Weighted average by Cap. | -1.71% | -0.46% | +31.05% | +89.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18.81B 17.15B 15.85B 14.31B 26.95B 1,758B 28.04B 191B 75.59B 949B 70.57B 69.1B 2,998B | 20.17B 18.38B 16.99B 15.33B 28.88B 1,885B 30.06B 205B 81.02B 1,017B 75.65B 74.07B 3,213B |
| Net income | 6.43B 5.86B 5.41B 4.89B 9.2B 601B 9.58B 65.24B 25.82B 324B 24.1B 23.6B 1,024B | 6.56B 5.98B 5.53B 4.99B 9.39B 613B 9.78B 66.59B 26.35B 331B 24.6B 24.09B 1,045B |
| Net Debt | -7.17B -6.53B -6.04B -5.45B -10.27B -670B -10.68B -72.77B -28.8B -362B -26.89B -26.33B -1,142B | -12.52B -11.41B -10.55B -9.52B -17.93B -1,170B -18.66B -127B -50.29B -631B -46.95B -45.97B -1,994B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/11/26 | USD 957.76 | +0.56% | 933,408 |
| 16/11/26 | USD 952.40 | -0.32% | 700,861 |
| 13/11/26 | USD 955.47 | +0.45% | 1,165,717 |
| 12/11/26 | USD 951.19 | -0.86% | 1,211,308 |
| 11/11/26 | USD 959.41 | +4.73% | 1,233,521 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions

















